# Junta clínica — PT-pseudo_5af00f9153c2 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_5af00f9153c2",
  "pid": "PT-pseudo_5af00f9153c2",
  "task": 1,
  "psa": 11.2,
  "age": 64,
  "months": 2,
  "pirads": "5",
  "psad": 0.18,
  "psav": 1.9,
  "psap": 7.5,
  "vol": 61.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8541575,
  "medhx": "Type 2 diabetes, Hypercholesterolaemia, Chronic kidney disease",
  "meds": "metformin, empagliflozin, atorvastatin, simvastatin, rosuvastatin",
  "notes": "PSA 11.2 ng/mL. PI-RADS 5. PSAD 0.18. Prostate volume 61 mL. csPCa 0.85.",
  "pmhx": [
    "Type 2 diabetes",
    "Hypercholesterolaemia",
    "Chronic kidney disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "95 kg",
    "height": "173 cm",
    "bmi": "31.7",
    "bp": "99/73 mmHg",
    "hr": "81 bpm",
    "smoking": "Ex-smoker (29 pack-yr, quit 2001)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "31 Jan 2025",
  "enc_ref": "Dr. P. van Dijk (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Evaluation initiated after documenting a sustained PSA elevation alongside a previous biopsy result establishing ISUP grade group 4 malignancy."
    },
    {
      "s": "History",
      "t": "A 64-year-old factory supervisor, currently cohabiting with his partner after a divorce, seeks re-assessment of a known prostate malignancy. His PSA values have climbed steadily from 3.3 ng/mL in early 2023 to the present 11.2 ng/mL. Underlying type 2 diabetes and chronic kidney disease are managed with metformin and empagliflozin, while hypercholesterolaemia is addressed through a combination of atorvastatin, simvastatin, and rosuvastatin. His estimated glomerular filtration rate has held steady beneath 60 mL/min/1.73m2. Urological discomfort is negligible, reflected by an IPSS score of 4, and he denies any blood in the urine or voiding difficulties. A significant smoking background of 29 pack-years ended in 2001; alcohol consumption remains limited to four units per week. He favors weekend gardening over formal exercise routines. Recent non-urological care included a standard chest radiograph and an audiology check for mild age-related hearing shifts, alongside a persistent sleep disturbance he links to occupational stress. Due to residing over ninety minutes from the clinic, he has asked that telephone consultations be utilized whenever medically suitable."
    },
    {
      "s": "Physical examination",
      "t": "Digital rectal assessment: Normal DRE — prostate measures approximately 60 g with a smooth, firm consistency and no detectable nodules or asymmetry.\nSystemic evaluation shows no abnormalities. Vital parameters remain stable at a blood pressure of 99/73 mmHg and a heart rate of 81 bpm. Body mass index registers at 31.7, aligning with his reported activity levels. Peripheral lymph nodes are non-palpable, and suprapubic regions exhibit no tenderness."
    }
  ],
  "occupation": "factory supervisor",
  "marital": "Divorced",
  "living": "Lives with partner",
  "next_of_kin": "Sibling (brother)",
  "recent_other": [
    "Audiology — hearing test",
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "4 units / week",
  "exercise": "Gardening, no structured exercise",
  "ipss": "IPSS score: 4/35 (mild LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_5af00f9153c2
Task: 1

Encounter: Urology - outpatient on 31 Jan 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 64-year-old male
  - PSA: 11.2 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.18 ng/mL²
  - PSA velocity: 1.9 ng/mL/yr
  - Prior PSA: 7.5 ng/mL
  - Prostate volume: 61.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8541575 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Hypercholesterolaemia, Chronic kidney disease
  - Problem list / PMHx: Type 2 diabetes, Hypercholesterolaemia, Chronic kidney disease
  - Current medication: metformin, empagliflozin, atorvastatin, simvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 11.2 ng/mL. PI-RADS 5. PSAD 0.18. Prostate volume 61 mL. csPCa 0.85.

Vitals: weight 95 kg, height 173 cm, BMI 31.7, BP 99/73 mmHg, HR 81 bpm. Smoking: Ex-smoker (29 pack-yr, quit 2001).

Chief complaint: Evaluation initiated after documenting a sustained PSA elevation alongside a previous biopsy result establishing ISUP grade group 4 malignancy.

History: A 64-year-old factory supervisor, currently cohabiting with his partner after a divorce, seeks re-assessment of a known prostate malignancy. His PSA values have climbed steadily from 3.3 ng/mL in early 2023 to the present 11.2 ng/mL. Underlying type 2 diabetes and chronic kidney disease are managed with metformin and empagliflozin, while hypercholesterolaemia is addressed through a combination of atorvastatin, simvastatin, and rosuvastatin. His estimated glomerular filtration rate has held steady beneath 60 mL/min/1.73m2. Urological discomfort is negligible, reflected by an IPSS score of 4, and he denies any blood in the urine or voiding difficulties. A significant smoking background of 29 pack-years ended in 2001; alcohol consumption remains limited to four units per week. He favors weekend gardening over formal exercise routines. Recent non-urological care included a standard chest radiograph and an audiology check for mild age-related hearing shifts, alongside a persistent sleep disturbance he links to occupational stress. Due to residing over ninety minutes from the clinic, he has asked that telephone consultations be utilized whenever medically suitable.

Physical examination: Digital rectal assessment: Normal DRE — prostate measures approximately 60 g with a smooth, firm consistency and no detectable nodules or asymmetry.
Systemic evaluation shows no abnormalities. Vital parameters remain stable at a blood pressure of 99/73 mmHg and a heart rate of 81 bpm. Body mass index registers at 31.7, aligning with his reported activity levels. Peripheral lymph nodes are non-palpable, and suprapubic regions exhibit no tenderness.

Patient info: factory supervisor; Divorced; Lives with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 4 units / week; exercise Gardening, no structured exercise; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Radiology — chest X-ray (routine).
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.58
  uncertainty  +/- 0.11 epistemic (95% band 0.36-0.80); among patients I cannot tell apart the outcome was 0.98 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.74: PI-RADS 5, PSA 12.0, PSAD 0.28, age 61, DRE Normal -> DEFER (borderline). He wrote: "Young patient with elevated PSA (>10), elevated PSA density, PIRADS5 and ISUP GG2 disease -> low threshold for recommending curative treatment. IF patient does not want…"
  2. distance 1.00: PI-RADS 5, PSA 19.0, PSAD 0.37, age 65, DRE Normal -> DEFER (clear). He wrote: "Patient needs treatment without repeat biopsy as earlier biopsy showed ISUP4"
  3. distance 1.16: PI-RADS 5, PSA 11.0, PSAD 0.108, age 70, DRE Normal -> BIOPSY (borderline). He wrote: "Patient on Activ Surveillance with severe LUTS symptoms. There are two options , recommend surgery direkt or do a new biopsy."

PRECEDENT: DEFER (weighted vote 0.27 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a repeat biopsy after a negative biopsy should be considered dependent on risk factors such as PSA density and PI-RADS score. It states, "follow-up or direct repeat biopsy should be considered dependant of risk factors (e.g. PSA density, PI-RADS score)."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I find the suggestion of biopsy is not decisive because the guideline makes the decision dependent on specific variables like PSA density and PI-RADS score, which are not the sole determinants here. EXPERT-COHORT, the finding that the panel does not determine the decision is consistent with the guideline's emphasis on these variables being necessary for decision-making.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the rate of PSA: the guideline suggests that a PSA change alone should not change management based on its weak link with grade progression

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on the documented grade of the prior biopsy and the surveillance plan detailed in the previous notes, as the panel alone is inconclusive.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size or extraprostatic extension require re-sampling?
  psa_trend (get_psa_trend) -> Does the rate of PSA change alone warrant a change in management?
  previous_notes (get_previous_notes) -> What is the documented grade of the prior biopsy, and is there a surveillance protocol?
  laboratory_results (get_lab_results) -> Does the full lab panel provide any missing context for the decision?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason/ISUP) of the prior biopsy?
  Q2. Is the patient on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size and zone of the index lesion, as the report words it: "a discrete hypointense focus occupies the left peripheral zone near the base-mid transition, spanning roughly 18 x 15 x 12 mm."

psa_trend
Does the rate of PSA change alone warrant a change in management?
The rate of PSA change alone warrant a change in management: PSA rose from 3.8 (Mar 2023) to 11.2 (Jan 2025), with a velocity of 1.9 ng/mL/yr.

previous_notes
What is the documented grade of the prior biopsy, and is there a surveillance protocol?
The documented grade of the prior biopsy is not explicitly stated in the retrieved notes, and there is no explicit mention of a surveillance protocol with a confirmatory biopsy due.

laboratory_results
Does the full lab panel provide any missing context for the decision?
The full lab panel shows PSA 11.2 ng/mL on 25 Dec 2024, Free PSA 2.15 ng/mL (19%), and eGFR <60 mL/min/1.73m2.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes and other data provided sufficient context regarding the prior biopsy status and surveillance.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 finding from the mpMRI report.
PSA velocity of 1.9 ng/mL/yr, indicating a significant rate of rise.

AGAINST sampling this patient now
The previous notes do not document the documented grade of the prior biopsy.
The EAU guideline suggests that a PSA change alone should not change management based on its weak link with grade progression.

WHERE THIS LEANS
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 11.20 ng/mL over 5 points spanning 22 months; velocity +3.98 ng/mL per year; doubling time about 14 months.
PROJECTION at 6 months: 15.4 ng/mL, conformal 95% band 4.4-53.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.56
  uncertainty  +/- 0.09 epistemic (95% band 0.39-0.73), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.58  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.56  ('discuss' tier, fusion_full; weight 1.5)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.27  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.57 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: borderline. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the Registrar appear to have addressed the moderator's questions to the extent possible. The `previous_notes` explicitly state that the documented grade of the prior biopsy is not explicitly stated, and there is no explicit mention of a surveillance protocol.

ALIGNMENT WITH THE PANEL
The panel protocol concluded with a weighted vote for BIOPSY (p=0.57), which aligns with the expert consensus, despite the lack of a documented prior grade. The retrieved information confirms the uncertainty noted by the experts regarding the decision point.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason/ISUP) of the prior biopsy? Answered: Not explicitly stated in the retrieved notes.
Q2. Is the patient on a surveillance protocol with a confirmatory biopsy due? Answered: No explicit mention of a surveillance protocol was found.

WHAT CARRIES WEIGHT, AND WHY
The documented grade of the prior biopsy is the most critical missing piece, as the EAU guideline emphasizes that the documented grade dictates the next step. The PSA velocity is also noted, but the guideline suggests this alone is a weak link regarding grade progression.

MY SUGGESTION TO THE CHAIR
Given that the critical information regarding the prior biopsy grade and surveillance status is missing from the retrieved documents, the panel's decision to proceed with a biopsy, based on the weighted expert consensus, is supported by the current evidence base, though the decision remains technically incomplete without that specific data.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: borderline)

64y/o, PSA 11.2, PSAD 0.18, PI-RADS 5, prior positive biopsy with undocumented grade. Rising PSA velocity of 1.9 ng/mL/yr suggests progression. Lack of prior biopsy grade mandates sampling to determine next step.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
